EYPT - EyePoint Pharmaceuticals, Inc.
IEX Last Trade
7.34
-1.570 -21.390%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:14:51 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$8.91
-1.57
-17.62%
Fundamental analysis
17%
Profitability
0%
Dept financing
23%
Liquidity
75%
Performance
18%
Performance
5 Days
3.24%
1 Month
-20.59%
3 Months
-10.06%
6 Months
-11.26%
1 Year
-67.54%
2 Year
143.52%
Key data
Stock price
$7.34
DAY RANGE
$7.34 - $8.91
52 WEEK RANGE
$7.35 - $30.99
52 WEEK CHANGE
-$69.62
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Nancy S. Lurker
Region: US
Website: eyepointpharma.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: eyepointpharma.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.
Recent news